NCPA 2026 Q&A urges pharmacist judgment on emerging compounded therapies
Drug Topics interview addresses how community pharmacists should weigh clinical evidence before preparing newer compounded products.
MH
By Maren Holt · Senior Reporter, GLP-1
Oct 15 10:40 ETSource: Drug Topics
The wire
- 01Drug Topics published a Q&A from the NCPA 2026 meeting on emerging compounded therapies and the clinical judgment pharmacists must apply.
- 02Compounders fielding requests for newer injectable products are the direct audience, as demand outpaces established evidence and formal guidance.
- 03Specific therapies, speakers and recommendations are not detailed in the available text.
From the source
Read at drugtopics.comQ&A: Emerging Compounded Therapies Demand Pharmacist’s Clinical Judgment | NCPA 2026
